Research To Practice | Oncology Videos

Featuring perspectives from Ms Kristen B Battiato and Dr Jennifer Woyach, including the following topics: Introduction (0:00) Case: A woman in her early 70s responding to ibrutinib for 4 years (27:07) Case: A woman in her early 80s with TP53-mutant, del(17p) disease responding to acalabrutinib (38:02) Case: A man in his mid 50s with chronic lymphocytic leukemia/small lymphocytic leukemia treated for a year with obinutuzumab followed by venetoclax; no evidence of disease for 3 years (43:29) Case: A Cuban woman in her mid 60s with multiregimen-recurrent disease, now receiving venetoclax (53:17) NCPD information and select publications

Featuring perspectives from Dr Carlos M de Castro, including the following topics: Overview of paroxysmal nocturnal hemoglobinuria (PNH) (0:00) Complement C5 inhibition for patients with PNH (6:48) Proximal complement inhibitors for PNH management (17:17) CME information and select publications

Featuring perspectives from Dr Carlos M de Castro, including the following topics: Biology of paroxysmal nocturnal hemoglobinuria (PNH) (0:00) Evolution of the PNH treatment landscape (13:07) Selection and sequencing of therapies for patients with PNH (18:09) Overview and presentation of extravascular hemolysis (23:50) Case: A woman in her early 40s with PNH who developed Budd-Chiari syndrome and had an excellent response to C5 inhibition (26:57) Case: A woman in her early 40s with a suboptimal response to ecluizumab followed by an excellent response to pegcetacoplan on the PEGASUS trial (34:00) Case: A woman in her mid 40s who experienced breakthrough hemolysis with pegcetacoplan and was recently switched to iptacopan (38:40) CME information and select publications

Featuring perspectives from Dr David F McDermott and Dr Sumanta Kumar Pal, including the following topics: Introduction (0:00) ASCO 2023 (1:35) Management of Advanced Renal Cell Carcinoma (RCC) (17:19) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC (38:13) CME information and select publications

Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell, including the following topics: Introduction (0:00) First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Powell (7:32) Current Options for Relapsed EC; Promising Investigational Agents and Strategies — Dr Monk (32:39) Clinical Investigator Survey (43:41) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Dr Harry H Yoon, including the following topics: Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers Introduction (0:00) Adjuvant immunotherapy for GE cancers (1:54) First-line anti-PD-1/PD-L1 antibody-based regimens for metastatic HER2-negative GE cancer (13:11) Future role of novel immunotherapies/checkpoint inhibitors (20:57) Optimal Management of HER2-Positive GE Cancers Selection of first-line therapy for metastatic HER2-positive GE cancer (28:37) Selection of second-line therapy for metastatic HER2-positive GE cancer (36:56) Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches Selection of second-line therapy for metastatic HER2-negative GE cancer (42:11) Zolbetuximab/chemotherapy as first-line therapy for claudin 18.2-positive metastatic GE cancer (43:09) Use of circulating tumor DNA assays for patients with GE cancers (53:37) CME information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis, Prof Karim Fizazi, Dr Rana R McKay, Dr Alicia K Morgans and Dr A Oliver Sartor, including the following topics: Current Management of Nonmetastatic Prostate Cancer Introduction (0:00) Case: A man in his early 70s diagnosed with localized prostate cancer who underwent a radical prostatectomy in 2010 experiences rising prostate-specific antigen (PSA) from 0.18 to 0.4; PSA doubling time 7 months; PSMA PET-negative for other sites of disease — David S Morris, MD (1:26) Case: A man in his early 70s with M0 hormone-sensitive prostate cancer (HSPC) with PSA persistence after radical prostatectomy received androgen deprivation therapy (ADT) intensification with abiraterone/prednisone and went to the ER with hypertension, palpitations, headache and abnormal liver function tests — Sandy Srinivas, MD (15:58) Faculty presentation: Dr Morgans (19:29) New Considerations in Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Case: A man in his mid 60s with localized prostate cancer and biochemical recurrence 5 years after neoadjuvant and adjuvant leuprolide and intensity-modulated radiotherapy to the whole pelvis — Neeraj Agarwal, MD, FASCO (28:59) Case: A man in his early 80s who underwent radical prostatectomy 15 years ago and received radiotherapy and ADT for biochemical recurrences is now diagnosed with M0 castration-resistant prostate cancer with quickly rising PSA levels — Dr Morris (33:02) Faculty presentation: Prof Fizazi (41:54) Available and Emerging Strategies for Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) Discussion (53:41) Case: A man in his mid 60s diagnosed with metastatic HSPC and PSMA positivity in the pubic ramus, bilateral external iliac nodes and lungs — Dr Srinivas (57:03) Faculty presentation: Dr McKay (1:03:01) Identification and Management of mCRPC with a Homologous Recombination Repair (HRR) Gene Abnormality Case: A man in his early 50s with mCRPC after enzalutamide receives olaparib; somatic BRCA2 mutation; TP53 mutation on liquid biopsy — Dr Agarwal (1:18:21) Case: A man in his early 70s with high-grade localized prostate cancer treated with proton beam therapy and ADT for 2 years now has rising PSA and CT scan positive for retroperitoneal node; somatic BRCA2, TP53, FOXA1 and MEN1 mutations; microsatellite stable — Dr Morris (1:21:59) Faculty presentation: Dr Antonarakis (1:30:22) Management of Progressive mCRPC Case: A man in his late 70s with multiregimen-refractory mCRPC and a gBRCA2 mutation receives olaparib with a sustained response for several years — Dr Srinivas (1:43:10) Faculty presentation: Dr Sartor (1:48:35) CME information and select publications

Featuring perspectives from Dr Ian W Flinn, including the following topics: Hodgkin Lymphoma Introduction (0:00) Case: A man in his late 30s with well-controlled HIV and newly diagnosed Stage IV classic Hodgkin lymphoma receives brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD) — Neil Morganstein, MD (2:30) Case: A man in his early 60s with classic Hodgkin lymphoma with a left lower lung mass and extensive regional lymphadenopathy receives brentuximab vedotin with AVD on the Phase III SWOG-S1826 trial — Ranju Gupta, MD (6:45) Mantle Cell Lymphoma (MCL) Case: A man in his late 50s with newly diagnosed MCL blastoid variant — Zanetta S Lamar, MD (16:27) Case: A man in his mid 50s with newly diagnosed Stage IV MCL — Shams Bufalino, MD (21:23) Follicular Lymphoma Case: A man in his mid 60s with incidental diagnosis of Grade IIIA follicular lymphoma after admission to the hospital for a stroke — Bhavana (Tina) Bhatnagar, DO (36:28) Case: A woman in her late 30s with extensive lymphadenopathy is diagnosed with Grade I/II follicular lymphoma and receives bendamustine/rituximab — Dr Morganstein (39:04) Diffuse Large B-Cell Lymphoma (DLBCL) Case: A physically independent man in his early 80s with DLBCL and multiple comorbidities, including cardiac issues and peripheral neuropathy, experiences disease progression after R-GCVP — Syed F Zafar MD (49:53) Case: A man in his mid 70s who presented with rapidly progressive proptosis of the left eye is diagnosed with DLBCL and receives R-CHOP and methotrexate CNS prophylaxis — Dr Lamar (55:21) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Mrs Amanda K Wagner, including the following topics: Introduction (0:00) Colorectal Cancer (10:18) Gastroesophageal Cancers (39:21) NCPD information and select publications

Featuring perspectives from Dr John N Allan, Dr Shaji K Kumar, Dr Ann S LaCasce, Dr Sagar Lonial, Dr Loretta J Nastoupil and Dr Susan O'Brien, including the following topics: Multiple Myeloma Introduction (0:00) Initial treatment of newly diagnosed multiple myeloma (MM) (1:51) Sequencing of therapies for relapsed/refractory MM (21:34) Lymphoma Hodgkin lymphoma (52:12) Diffuse large B-cell lymphoma and follicular lymphoma (1:05:30) Mantle cell lymphoma (1:31:17) Chronic Lymphocytic Leukemia First-line treatment of chronic lymphocytic leukemia (1:41:23) Relapsed/refractory disease (2:14:23) Richter's transformation (2:22:50) CME information and select publications